Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Demeclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CASP7 | P55210 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demeclocycline SCHEMBL41286 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL28251348 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL6549174 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL41287 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL23247280 | 0.99 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL29355123 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL20716691 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL20952687 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL3252 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT | |
| Demeclocycline SCHEMBL5503953 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| WO-2024187239-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | claimed |
| US-20230158259-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | TOPELIA AUST LIMITED (652 771 670) (AU) | 2023-05-25 | — | — | US | claimed |
| CN-115955965-A | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | 拓比利亚欧斯特有限公司 | 2023-04-11 | — | — | CN | claimed |
| US-20230081837-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2023-03-16 | — | — | US | claimed |
| EP-4138832-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | Topelia Aust Limited (AU) | 2023-03-01 | — | — | EP | claimed |
| WO-2022236364-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-11-17 | — | — | WO | claimed |
| EP-3989981-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | Topelia Australia Pty Ltd (AU) | 2022-05-04 | — | — | EP | claimed |
| US-20260115164-A1 | THERAPEUTIC DRUG COMBINATIONS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | TOPELIA AUST LTD (AU) | 2026-04-30 | — | — | US | disclosed |
| US-20260033494-A1 | PLANT ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | TEXAS A & M UNIV SYS (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | disclosed |
| US-12458025-B2 | Plant antimicrobial compositions and methods of use thereof | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2025-11-04 | — | — | US | disclosed |
| CN-114765956-A | Combinations of zidovudine and tetracycline antibiotics | 赫尔普百治疗有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022124243-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | 東和薬品株式会社 | 2022-06-16 | — | — | WO | disclosed |
| EP-3989981-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | Topelia Australia Pty Ltd (AU) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022047243-A1 | METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER | ENOSI LIFE SCIENCES CORP. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458025-B2 | Plant antimicrobial compositions and methods of use thereof | DDT, CDA, UROD | MEN1 3701/4885KMT2A 2534/4885TDP1 451/4885 |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | ACE, MAVS, SARS1 | MEN1 247/4885KMT2A 4618/4885TDP1 4169/4885 |
| US-20260033494-A1 | PLANT ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | MYB, DDT, PDE1C | MEN1 3657/4885KMT2A 2836/4885TDP1 585/4885 |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ZFX, ACE2, ZFR | MEN1 4830/4885KMT2A 641/4885TDP1 3576/4885 |
| US-20260115164-A1 | THERAPEUTIC DRUG COMBINATIONS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | SARS1, MAVS, ACE | MEN1 3925/4885KMT2A 4467/4885TDP1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.